Sports
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12 in San Antonio, Texas. These updates reflect Lilly's continued progress across key pathways in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, the most common form of breast cancer.1
About this update from Eli Lilly And Company
[{"type":"text","content":"Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-breaking oral presentation","length":221,"tagName":"p","attribs":{}},{"type":"text","content":"Updated safety and efficacy data to be presented from PIKALO-1, the Phase 1/2 trial of Lilly's pan-mutant-selective PI3Kα inhibitor, which will be advanced into the Phase 3 PIKALO-2 study","length":191,"tagName":"p","attribs":{}},{"type":"text","content":"New subgroup analysis from the Phase 3 monarchE trial that explores outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2– high-risk early breast cancer","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Nov. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12 in San Antonio, Texas. These updates reflect Lilly's continued progress across key pathways in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, the most common form of breast cancer.1","length":508,"tagName":"p"},{"type":"text","content":"Presentation Highlights","length":23,"tagName":"p"},{"type":"text","content":"Inluriyo (imlunestrant; estrogen receptor antagonist)In a late-breaking oral presentation, Lilly will share updated results from the Phase 3 EMBER-3 trial evaluating Inluriyo (imlunestrant) alone and in combination with Verzenio (abemaciclib), in patients with ER+, HER2– advanced or metastatic breast cancer. The presentation will feature a pre-specified interim overall survival (OS) analysis, with updates on progression-free survival (PFS) and time to chemotherapy (TTC). In addition, a poster presentation will provide results of an exploratory analysis of early changes in circulating tumor DNA (ctDNA) and correlation to clinical outcomes.","length":647,"tagName":"p"},{"type":"text","content":"Verzenio (abemaciclib; CDK4/6 inhibitor)In a poster presentation, Lilly will share results from a subgroup analysis of the Phase 3 monarchE trial, evaluating adjuvant abemaciclib plus endocrine therapy by nodal status in patients ...